Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
MT Newswires on MSN1d
US Equity Futures Gain as Investors Search for Fresh Catalysts After Fed Rate CutUS equity futures were higher ahead of Monday's opening bell as traders searched for fresh catalysts after last week's interest-rate cut from the Federal Reserve. The Dow Jones Industrial Average ...
A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...
CloseCurlyDoubleQuote; In April 2024, Black Diamond described real world evidence of the evolving EGFR mutation landscape in patients with non-small cell lung cancer (NSCLC) and the potential of BDTX ...
Workers already have asked it more than 500,000 questions. BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed ...
These results are seen as setting benchmarks for Black Diamond's BDTX-1535, particularly in its ongoing first-line non-classical cohort. The targeted outcomes for BDTX-1535 include an objective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback